Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Somewhat Bullish +50

Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill

📈 Amazon Pharmacy will stock Eli Lilly's new GLP-1 pill Foundayo at One Medical kiosks starting April 9, 2026, with plans to expand to 4,500 locales by year-end.

💊 Foundayo is sold directly to patients through LillyDirect at $149 per month for the lowest dose, with Amazon acting as a key dispensing partner.

🏢 Eli Lilly stands as the clearest beneficiary due to direct revenue flow from Amazon Pharmacy filling prescriptions via the LillyDirect channel.

📉 Novo Nordisk faces increased competitive pressure as its Wegovy pill now shares Amazon kiosks with Foundayo following recent market share losses.

💼 CVS Health benefits across multiple arms including Caremark for insurance claims and retail pharmacies for dispensing existing scripts.

🚀 Viking Therapeutics stands to gain indirectly as a stronger GLP-1 market validates its pipeline asset VK2735 currently in Phase 3 trials.

📊 Lilly reported $11.67 billion combined revenue from Zepbound and Mounjaro in Q4 2025, driving full-year growth to $65.18 billion.

🤝 Amazon invested over $4 billion in 2025 to expand delivery options, with Foundayo's non-refrigerated pill format fitting the kiosk model.

💬 Eli Lilly CEO David Ricks emphasized that deep pipelines and platforms like LillyDirect will expand their global health impact entering their 150th year.

🤝 Amazon CEO Andy Jassy highlighted a $200 billion capital expenditure expectation for 2026, positioning pharmacy within the broader thesis of faster customer reach.

⚠️ Novo Nordisk issued cautious 2026 guidance predicting adjusted sales growth between -5% and -13% due to pricing headwinds and competition.

🏭 Lilly is scaling manufacturing with a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support demand.

🔬 Viking Therapeutics CEO Brian Lian focused on clinical milestones rather than commercial distribution given its pre-revenue status.

💰 Pharmacy sub-segment revenue for CVS grew 15.2% in Q4 2025 to $31.38 billion as same-store prescription volume accelerated by 9.7%.

🚚 Amazon's One Medical kiosk model is validated for future drug categories through every Foundayo prescription filled via the partnership.

Bullish Signals
  • Eli Lilly generated $11.67 billion in combined quarterly revenue from Zepbound ($4.26 billion) and Mounjaro ($7.41 billion) in Q4 2025, reflecting strong market uptake.
  • Full-year 2025 revenue for Eli Lilly reached $65.18 billion, representing a significant 44.7% year-over-year growth.
  • Management at Eli Lilly has raised full-year 2026 revenue guidance to a range of $80 billion to $83 billion, signaling strong confidence in future performance.
  • Lilly's manufacturing expansion includes major investments like a new $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe to support global scale.
  • Amazon Pharmacy has expanded its reach to serve nearly 100 million customers with same-day delivery, creating deep recurring revenue opportunities through the healthcare channel.
  • Amazon invested over $4 billion in 2025 alone to triple its companywide delivery options, strengthening its healthcare integration strategy.
  • Viking Therapeutics sees indirect growth benefits as increased accessibility of GLP-1 drugs like Foundayo expands the total addressable market for its VK2735 pipeline.
  • Novo Nordisk expressed optimism about promising early uptake from the US launch of its Wegovy pill in 2026, despite broader market headwinds.
Risk Factors
  • Novo Nordisk's U.S. operations declined 15% in Q4 2025 due to lower realized prices and market share losses.
  • Novo Nordisk issued cautious 2026 guidance calling for adjusted sales growth of −5% to −13% at constant exchange rates amid intensifying competition.
  • Viking Therapeutics lacks both approved products and a direct Amazon Pharmacy relationship, relying entirely on future regulatory approval for revenue generation.
  • Lilly's manufacturing expansion requires significant capital allocation with $6 billion invested in an Alabama facility and $3 billion in a European oral medicine facility.
  • Amazon plans to invest approximately $200 billion in capital expenditures across the company in 2026, which may strain cash flow despite strong revenue growth.
  • Pharmacy sub-segment revenue growth of 15.2% for CVS reflects rising adoption but exposes the company to competitive pressures from Amazon's same-day delivery model.
  • Lilly's LillyDirect channel sells directly to cash-pay customers at $149 per month, potentially limiting payer relationships and insurance coverage penetration compared to injectables.
Full Analysis
On April 9, 2026, Amazon announced that its pharmacy unit will begin stocking Eli Lilly's new GLP-1 weight-loss pill, Foundayo, at One Medical kiosks with same-day home delivery plans to reach 4,500 locales by the end of 2026. This expansion integrates Amazon Pharmacy as a key dispensing partner for LillyDirect, which began selling Foundayo directly to cash-pay customers at $149 per month for the lowest dose. The strategic move positions Eli Lilly as a primary beneficiary, with its GLP-1 portfolio generating $11.67 billion in Q4 2025 revenue alone through Zepbound and Mounjaro, contributing significantly to a full-year 2025 revenue of $65.18 billion that rose 44.7% year-over-year. Management projects Lilly's revenue could reach between $80 billion and $83 billion in 2026, while CEO David Ricks emphasized the company's ability to reach more patients through platforms like LillyDirect as it enters its 150th year. Several other companies face varying degrees of impact from this distribution shift. CVS Health benefits across its retail pharmacies, Caremark pharmacy benefit manager, and Aetna insurance operations, with same-store prescription volume growing 9.7% in Q4 2025 and pharmacy sub-segment revenue reaching $31.38 billion in the same quarter to help achieve its ambition of becoming the most trusted health care company in America. Novo Nordisk faces increased competitive pressure as Amazon Pharmacy adds Foundayo to its kiosks where Wegovy is already stocked; the company reported a 15% decline in U.S. operations in Q4 2025 and issued guidance for adjusted sales growth between -5% and -13% at constant exchange rates in 2026, though President Mike Doustdar remains encouraged by early uptake of the Wegovy pill launch. Viking Therapeutics lacks an approved product or current Amazon relationship but sees indirect benefits as clinical validation strengthens its investment case for Phase 3 asset VK2735 with over 4,500 patients enrolled. Amazon CEO Andy Jassy stated that while investing approximately $200 billion in capital expenditures in 2026 across areas like AI and robotics, the pharmacy business remains central to its strategy of reaching customers faster and more directly through Prime membership stickiness. Foundayo is particularly well-suited for this model as it requires no refrigeration compared to injectable competitors. Eli Lilly plans to support this scale with manufacturing expansion, including a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe. While Amazon builds recurring revenue from healthcare relationships and CVS maintains its role in processing insurance claims behind retail fronts, Novo Nordisk must navigate pricing headwinds in an increasingly competitive market where the pill format removes cold-chain barriers previously limiting kiosk access to weight-loss drugs.